Search

408 Result(s)
Sort by

Stargardt Disease

Stargardt Disease

Stargardt Disease is a hereditary condition which causes degeneration of cells in the retina at the back of the eye.
CHMP_opinion_nintedanib_ILD_PF

CHMP_opinion_nintedanib_ILD_PF

Nintedanib received a CHMP positive opinion for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
Sarcoma

Sarcoma

Hear from Gary Schwartz, MD, Director of the Case Comprehensive Cancer Center, Cleveland, Ohio, talk about his expert perspectives on sarcoma.
Expert Advice from Dr Clare Shaw

Expert Advice from Dr Clare Shaw

Consultant oncology dietitian Dr Clare Shaw shares her advice on some of the most common cancer nutrition misunderstandings.
Combatting Appetite Loss

Combatting Appetite Loss

Discover tips on how to combat appetite loss from Taking Cancer On Through Flavour
FIBRONEER™ Phase III program initiated

FIBRONEER™ Phase III program initiated

FIBRONEER™ Phase III program initiated globally to evaluate BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor
Innovation in medicinal chemistry

Innovation in medicinal chemistry

Darryl McConnell, Research Site Head, Austria and Jürgen Mack, Medicinal Chemistry, explain how we are working to unlock unsolved diseases
FDA-approves-nintedanib-in-SSc-ILD

FDA-approves-nintedanib-in-SSc-ILD

FDA approves Ofev® as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD
Disentangling fibrosis

Disentangling fibrosis

Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.
Ofev®

Ofev®

Ofev® is a prescription medication used to treat people with idiopathic pulmonary fibrosis (IPF) systemic sclerosis-associated interstitial lung disease (SSc-ILD) and other chronic fibrosing interstitial lung diseases with a progressive phenotype